Summary
Background Stratifying the risk of colorectal cancer (CRC) based on polygenic risk scores (PRSs) within populations has the potential to optimize screening and develop targeted prevention strategies.
Methods A meta-analysis of eleven genome-wide association studies (GWAS), comprising 16 871 cases and 26 328 controls, was performed to capture CRC susceptibility variants. Genetic models with several candidate PRSs were generated from Scottish CRC case–control studies (6478 cases and 11 043 controls) for prediction of overall and site-specific CRC. Model performance was validated in UK Biobank (4800 cases and 20 287 controls). The 10-year absolute risk of CRC was estimated by modelling PRS with age and sex using the CRC incidence and mortality rates in the UK population.
Findings A weighted PRS including 116 CRC SNPs (wPRS116) showed the strongest performance. Deconstructing the PRS into multiple genetic risk regional scores or inclusion of additional SNPs that did not reach genome-wide significance did not provide any further improvement on predictive performance. The odds ratio (OR) for CRC risk per SD of wPRS116 in Scottish dataset was 1·46 (95%CI: 1·41-1·50, c-statistics: 0·603). Consistent estimates were observed in UK Biobank (OR=1·49, 95%CI: 1·44-1·54, c-statistics: 0·610) and showed no substantial heterogeneity among tumor sites. Compared to the middle quintile, those in the highest 1% of PRSs had 3·25-fold higher risk and those in the lowest 1% had 0·32-fold lower risk of developing CRC. Modelling PRS with age and sex in the general UK population allows the identification of a high-risk group with 10-year absolute risk ≥5%.
Interpretation By optimizing wPRS116, we show that genetic factors increase predictive performance but this increment is equivalent to the extraction of only one-tenth of the genetic susceptibility. When employing genetic risk profiling in population settings it provides a degree of risk discrimination that could, in principle, be integrated into population-based screening programs.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
E.T. is supported by a Cancer Research UK Career Development Fellowship (C31250/A22804). The work was supported by Programme Grant funding from Cancer Research UK (C348/A12076) and by funding for the infrastructure and staffing of the Edinburgh CRUK Cancer Research Centre. This work was also funded by a grant to MGD as Project Leader with the MRC Human Genetics Unit Centre Grant (U127527198). At the Institute of Cancer Research, this work was supported by Cancer Research UK (C1298/A25514). Additional support was provided by the National Cancer Research Network. In Birmingham, funding was provided by Cancer Research UK (C6199/A16459).
Author Declarations
All relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
Any clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.
Yes
Data Availability
All data referred to is available in the manuscript.
